Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Up 17,702.6% in May

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a large increase in short interest in May. As of May 29th, there was short interest totaling 68,896 shares, an increase of 17,702.6% from the May 14th total of 387 shares. Based on an average trading volume of 778,450 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.1% of the company’s stock are short sold.

Matinas Biopharma Stock Performance

NYSEAMERICAN:MTNB opened at $0.80 on Wednesday. The firm has a market cap of $5.11 million, a price-to-earnings ratio of -0.40 and a beta of 1.67. Matinas Biopharma has a 52 week low of $0.48 and a 52 week high of $3.09. The firm has a 50-day moving average price of $0.62 and a two-hundred day moving average price of $0.65.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.30) EPS for the quarter.

Institutional Investors Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC acquired a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma as of its most recent filing with the SEC. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.